PI Pharma Insight

BNF presentation directory

Explore British National Formulary presentations, drill into dispensing trend data, and identify which pharmacies drive the greatest usage of each medicine.

Reset
Presentation Product Chemical substance Chapter Items dispensed
Mefenamic acid 250mg/5ml oral suspension
1001010N0AAAGAG
Mefenamic acid Mefenamic acid Musculoskeletal and Joint Diseases No data available
Mefenamic acid 500mg/5ml oral suspension
1001010N0AAAHAH
Mefenamic acid Mefenamic acid Musculoskeletal and Joint Diseases No data available
Meloxicam 15mg suppositories
1001010AAAAACAC
Meloxicam Meloxicam Musculoskeletal and Joint Diseases No data available
Meloxicam 15mg/5ml oral suspension
1001010AAAAAIAI
Meloxicam Meloxicam Musculoskeletal and Joint Diseases No data available
Meloxicam 3.75mg/5ml oral suspension
1001010AAAAAGAG
Meloxicam Meloxicam Musculoskeletal and Joint Diseases No data available
Meloxicam 7.5mg suppositories
1001010AAAAADAD
Meloxicam Meloxicam Musculoskeletal and Joint Diseases No data available
Meloxicam 7.5mg/5ml oral suspension
1001010AAAAAHAH
Meloxicam Meloxicam Musculoskeletal and Joint Diseases No data available
Mestinon 60mg/5ml syrup
1002010Q0BBAEBF
Mestinon Pyridostigmine bromide Musculoskeletal and Joint Diseases No data available
Metalcaptase gastro-resistant 150mg tablets
1001030F0BDAAAM
Metalcaptase Penicillamine Musculoskeletal and Joint Diseases No data available
Metalcaptase gastro-resistant 300mg tablets
1001030F0BDABAN
Metalcaptase Penicillamine Musculoskeletal and Joint Diseases No data available
Methocarbamol 375mg/5ml oral suspension
1002020S0AAACAC
Methocarbamol Methocarbamol Musculoskeletal and Joint Diseases No data available
Methofill 27.5mg/0.55ml inj pre-filled injector
1001030U0BGAIBZ
Methofill (Rheumatism) Methotrexate Musculoskeletal and Joint Diseases No data available
Methofill 27.5mg/0.55ml inj pre-filled syringes
1001030U0BGASBN
Methofill (Rheumatism) Methotrexate Musculoskeletal and Joint Diseases No data available
Methotrexate 10mg/1ml inj pre-filled syringes
1001030U0AABBBB
Methotrexate (Rheumatism) Methotrexate Musculoskeletal and Joint Diseases No data available
Methotrexate 12mg/5ml oral liquid
1001030U0AAASAS
Methotrexate (Rheumatism) Methotrexate Musculoskeletal and Joint Diseases No data available
Methotrexate 15mg/1.5ml inj pre-filled syringes
1001030U0AABCBC
Methotrexate (Rheumatism) Methotrexate Musculoskeletal and Joint Diseases No data available
Methotrexate 15mg/5ml oral liquid
1001030U0AAARAR
Methotrexate (Rheumatism) Methotrexate Musculoskeletal and Joint Diseases No data available
Methotrexate 17.5mg/5ml oral liquid
1001030U0AAATAT
Methotrexate (Rheumatism) Methotrexate Musculoskeletal and Joint Diseases No data available
Methotrexate 18mg/5ml oral liquid
1001030U0AAAXAX
Methotrexate (Rheumatism) Methotrexate Musculoskeletal and Joint Diseases No data available
Methotrexate 1mg/5ml oral liquid
1001030U0AAALAL
Methotrexate (Rheumatism) Methotrexate Musculoskeletal and Joint Diseases No data available
Methotrexate 20mg/1ml inj pre-filled syringes
1001030U0AABSBS
Methotrexate (Rheumatism) Methotrexate Musculoskeletal and Joint Diseases No data available
Methotrexate 20mg/5ml oral liquid
1001030U0AAAVAV
Methotrexate (Rheumatism) Methotrexate Musculoskeletal and Joint Diseases No data available
Methotrexate 22.5mg/5ml oral liquid
1001030U0AAAYAY
Methotrexate (Rheumatism) Methotrexate Musculoskeletal and Joint Diseases No data available
Methotrexate 25mg/1.25ml inj pre-filled syringes
1001030U0AABPBP
Methotrexate (Rheumatism) Methotrexate Musculoskeletal and Joint Diseases No data available
Methotrexate 25mg/2.5ml inj pre-filled syringes
1001030U0AABDBD
Methotrexate (Rheumatism) Methotrexate Musculoskeletal and Joint Diseases No data available

Why monitor BNF codes?

Link medicine usage to pharmacy and prescriber behaviour to find optimisation opportunities.

Track cost pressure

Identify presentations with rising spend and create intervention plans focused on switching opportunities or formulary alignment.

Understand demand drivers

Cross-reference high-volume medicines with local health priorities and prescriber activity to target support programs.